Jeito Capital
Also known as Jeito
Paris biopharma investor founded in 2018 by Rafaèle Tordjman; €1.6bn under management across Jeito I and Jeito II, backing mainly European clinical-stage biotech companies.
- HEADQUARTERS
- Paris, France
- FOUNDED
- 2018
- AUM
- €1.6B (2026)
- OUTSIDE CAPITAL
- Yes
- TEAM LISTED
- 10 people
FOCUS
- STAGES
- Series ASeries BGrowth
- SECTORS
- Biotech & Life Sciences
- ASSET MIX
- Venture capital
- GEOGRAPHY
- EuropeNorth America
WHAT IT IS
VC Fund. A fund manager investing capital raised from limited partners into startups.
ABOUT
Jeito Capital is an independent Paris portfolio management company, authorised by the AMF in 2019, that invests in biopharma companies developing therapies for severe diseases with high unmet medical need. It was founded in 2018 by Dr Rafaèle Tordjman, formerly a partner at Sofinnova Partners. Its first fund, Jeito I, closed at €534m ($630m) in 2021 and Jeito II closed at over €1bn ($1.2bn) in April 2026, bringing assets under management to €1.6bn. It has teams in Europe and the United States and invests in therapeutic areas including oncology, autoimmune and inflammatory diseases, ophthalmology, cardiology, obesity and neuromuscular disease.
INVESTMENT THESIS
Backs 15 to 20 clinical-stage biopharma companies per fund, primarily in Europe, and keeps investing at each value inflection point; Jeito II raises the average investment per company to up to €150m.
PORTFOLIO (12)
- HI-BioNOTABLEBiotech & Life Sciences · since 2022 · Acquired
- EyeBioNOTABLEBiotech & Life Sciences · since 2022 · Acquired
- Bionyra PharmaBiotech & Life Sciences · since 2026
- AdcendoBiotech & Life Sciences · since 2026
- Alveus TherapeuticsBiotech & Life Sciences · since 2026
- Odyssey TherapeuticsBiotech & Life Sciences · since 2025
- AzafarosBiotech & Life Sciences · since 2025
- Callio TherapeuticsBiotech & Life Sciences · since 2025
- Aviceda TherapeuticsBiotech & Life Sciences · since 2024
- CatalYmBiotech & Life Sciences · since 2022
- Alentis TherapeuticsBiotech & Life Sciences · since 2021
- Neogene TherapeuticsBiotech & Life Sciences · since 2020 · Acquired
TEAM
- Rafaèle TordjmanFounder & CEO · source
- Sabine DandiguianManaging Partner · source
- Ksenija PavleticGeneral Partner & Chief Commercial Officer · source
- Mehdi AinouchePartner · source
- Claudio Costa-NetoPartner & Chief Scientific Officer · source
- Pascal TouchonPartner · source
- Magdalena JonikasPartner · source
- Annette ClancyOperating Partner, M&A & Strategy · source
- Samit HirawatOperating Partner, Medical Strategy · source
- Sarah ShackeltonPartner, Talent · source
LINKS
FAQ
Jeito Capital is a VC fund based in Paris, France, founded in 2018.
Yes. Jeito Capital invests directly in private companies.
Jeito Capital invests at Series A, Series B and Growth stages in Biotech & Life Sciences.
Key people at Jeito Capital include Rafaèle Tordjman (Founder & CEO), Sabine Dandiguian (Managing Partner), Ksenija Pavletic (General Partner & Chief Commercial Officer) and Mehdi Ainouche (Partner).
Jeito Capital's investments include HI-Bio, EyeBio, Bionyra Pharma, Adcendo, Alveus Therapeutics, Odyssey Therapeutics, Azafaros and Callio Therapeutics, among others.
The most recent publicly reported investment by Jeito Capital is Bionyra Pharma ($165M Series A (co-lead with Sofinnova Partners)), announced in Jun 2026.
Yes. Jeito Capital manages capital from outside investors.